NASDAQ:XENE
Xenon Pharmaceuticals Inc. Stock News
$42.49
+1.84 (+4.53%)
At Close: May 01, 2024
Is Xenon Pharmaceuticals a Good Stock to Buy Now?
05:42am, Tuesday, 05'th Oct 2021
Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher.
Xenon Pharmaceuticals Announces Proposed Public Offering
04:08pm, Monday, 04'th Oct 2021
BURNABY, British Columbia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritte
Pharma Stock Soars to Record Highs After Epilepsy Drug Study Results
01:32pm, Monday, 04'th Oct 2021
Xenon Pharmaceuticals Inc (NASDAQ:XENE) stock is soaring today, up 90.8% to trade at $29.76 at last glance, after the company met its main goal in a phase 2 study of its epilepsy treatment XEN1101.
Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint
10:28am, Monday, 04'th Oct 2021
Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial m
Why Xenon Pharmaceuticals Stock Is Soaring Today
10:07am, Monday, 04'th Oct 2021
Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary en
Tesla Sets Delivery Records, but This Nasdaq Stock Was the Big Premarket Winner Monday
09:19am, Monday, 04'th Oct 2021
Markets are looking to open on a down note.
Why Xenon Pharmaceuticals Stock Is Screaming Higher Today
09:18am, Monday, 04'th Oct 2021
A positive mid-stage trial is powering this biotech stock higher today.
BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a
Are Options Traders Betting on a Big Move in Xenon (XENE) Stock?
09:57am, Monday, 20'th Sep 2021
Investors need to pay close attention to Xenon (XENE) stock based on the movements in the options market lately.
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
08:30am, Wednesday, 08'th Sep 2021
Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021 Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Sei
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer
08:30am, Monday, 23'rd Aug 2021
BURNABY, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Ken
Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2021 Results - Earnings Call Transcript
10:13pm, Wednesday, 11'th Aug 2021
Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2021 Results - Earnings Call Transcript
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Lags Revenue Estimates
06:38pm, Wednesday, 11'th Aug 2021
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.08% and -13.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 11'th Aug 2021
Topline Data from XEN1101 Phase 2b “X-TOLE” Clinical Trial Anticipated Late September to Mid-October 2021
Xenon Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
05:53pm, Tuesday, 10'th Aug 2021
BURNABY, British Columbia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one in
